Samantha Jaglowski

17.1k total citations · 1 hit paper
152 papers, 2.9k citations indexed

About

Samantha Jaglowski is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Samantha Jaglowski has authored 152 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Genetics, 58 papers in Pathology and Forensic Medicine and 58 papers in Oncology. Recurrent topics in Samantha Jaglowski's work include Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (57 papers) and CAR-T cell therapy research (40 papers). Samantha Jaglowski is often cited by papers focused on Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (57 papers) and CAR-T cell therapy research (40 papers). Samantha Jaglowski collaborates with scholars based in United States, Canada and India. Samantha Jaglowski's co-authors include Joseph M. Flynn, John C. Byrd, Kristie A. Blum, Amy J. Johnson, Xiaoli Zhang, Bruce R. Blazar, Amber Gordon, Joseph J. Buggy, Erin Hertlein and Jeffrey J. Jones and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Samantha Jaglowski

143 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

2011 607 citations Samantha Jaglowski, John C. Byrd et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samantha Jaglowski United States	24	1.5k	1.2k	992	940	896	152	2.9k
Julio Delgado Spain	35	1.6k 1.1×	1.3k 1.1×	1.1k 1.1×	1.0k 1.1×	939 1.0×	195	3.6k
David Westerman Australia	27	1.4k 1.0×	1.4k 1.2×	732 0.7×	776 0.8×	545 0.6×	125	2.8k
Farrukh T. Awan United States	33	2.0k 1.4×	1.6k 1.3×	935 0.9×	976 1.0×	1.3k 1.4×	199	3.7k
Stefano Molica Italy	31	1.9k 1.3×	1.4k 1.2×	671 0.7×	726 0.8×	980 1.1×	170	3.0k
Sameer A. Parikh United States	31	1.9k 1.3×	1.5k 1.3×	923 0.9×	540 0.6×	1.0k 1.1×	170	3.0k
Brian T. Hill United States	27	790 0.5×	962 0.8×	482 0.5×	1.2k 1.3×	475 0.5×	225	2.7k
Nishitha Reddy United States	21	1.0k 0.7×	1.4k 1.2×	511 0.5×	1.0k 1.1×	534 0.6×	116	2.3k
Simon Rule United Kingdom	30	1.6k 1.1×	2.4k 2.0×	593 0.6×	1.7k 1.8×	519 0.6×	155	3.4k
G.J. Ossenkoppele Netherlands	34	677 0.5×	812 0.7×	1.6k 1.6×	1.1k 1.2×	607 0.7×	84	3.3k
Marı́a Dolores Caballero Spain	32	586 0.4×	1.4k 1.1×	1.1k 1.1×	1.2k 1.3×	657 0.7×	74	2.8k

Countries citing papers authored by Samantha Jaglowski

Since Specialization

Citations

This map shows the geographic impact of Samantha Jaglowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samantha Jaglowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samantha Jaglowski more than expected).

Fields of papers citing papers by Samantha Jaglowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samantha Jaglowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samantha Jaglowski. The network helps show where Samantha Jaglowski may publish in the future.

Co-authorship network of co-authors of Samantha Jaglowski

This figure shows the co-authorship network connecting the top 25 collaborators of Samantha Jaglowski. A scholar is included among the top collaborators of Samantha Jaglowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samantha Jaglowski. Samantha Jaglowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Landsburg, Daniel J., Matthew J. Frigault, S.R. Foley, et al.. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. Journal for ImmunoTherapy of Cancer. 13(2). e009890–e009890. 3 indexed citations

Silberman, Pedro C., Yazeed Sawalha, Beth Christian, et al.. (2024). Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 42(16_suppl). 7033–7033. 2 indexed citations

Jiang, Justin, Audrey M. Sigmund, Qiuhong Zhao, et al.. (2024). Impact of chronic graft- versus -host disease on non-relapse mortality and survival. Leukemia & lymphoma. 65(11). 1698–1705. 1 indexed citations

Ho, Vincent T., Thomas R. Klumpp, Mitchell E. Horwitz, et al.. (2023). Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. Transplantation and Cellular Therapy. 29(9). 539–547. 1 indexed citations

Gray, Ashley, Catherine Chung, Lucia Seminario‐Vidal, et al.. (2023). Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil. JAAD Case Reports. 36. 82–88. 2 indexed citations

Faisal, Muhammad Salman, Walter Hanel, Timothy Voorhees, et al.. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 12(7). 8228–8237. 2 indexed citations

Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations

Munshi, Pashna N., Yue Chen, Kwang Woo Ahn, et al.. (2022). Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 28(8). 487.e1–487.e7. 11 indexed citations

Sigmund, Audrey M., Nathan Denlinger, Patrick Elder, et al.. (2021). Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. Blood. 138(Supplement 1). 3851–3851. 2 indexed citations

10.

Wall, Sarah, Ying Huang, Carolyn J. Presley, et al.. (2021). Increasing Number of Geriatric Assessment-Identified Deficits Associated with Non-Receipt of Transplant Among Older Adults. Transplantation and Cellular Therapy. 27(3). S437–S438. 1 indexed citations

11.

Chin, Kuo‐Kai, Haesook T. Kim, Vincent T. Ho, et al.. (2021). Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplantation and Cellular Therapy. 27(12). 990.e1–990.e7. 14 indexed citations

12.

Zhao, Qiuhong, Patrick Elder, Jonathan E. Brammer, et al.. (2020). Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. Leukemia & lymphoma. 62(4). 944–951. 5 indexed citations

13.

Jaglowski, Samantha, Zhen‐Huan Hu, Yiyun Zhang, et al.. (2019). Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 134(Supplement_1). 766–766. 62 indexed citations

14.

Wang, Michael, Javier Muñoz, André Goy, et al.. (2019). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Blood. 134(Supplement_1). 754–754. 18 indexed citations

15.

Klepin, Heidi D., Tanya M. Wildes, Rebecca L. Olin, et al.. (2019). Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood. 134(Supplement_1). 5819–5819. 2 indexed citations

16.

Awasthi, Rakesh, Constantine S. Tam, Ulrich Jaeger, et al.. (2018). Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Clinical Trials. 78(13).

17.

Rettig, Michael P., Geoffrey L. Uy, Asad Bashey, et al.. (2018). Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. Blood. 132(Supplement 1). 118–118. 1 indexed citations

18.

Epperla, Narendranath, Kwang Woo Ahn, Philippe Armand, et al.. (2017). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation. 24(1). 78–85. 7 indexed citations

19.

Awasthi, Rakesh, Constantine S. Tam, Ulrich Jaeger, et al.. (2017). Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 130. 5211–5211. 1 indexed citations

20.

El‐Jawahri, Areej, Joseph Pidala, Xiaoyu Chai, et al.. (2014). Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 20(9). 1341–1348. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact